With the introduction of the SYNTAX system, DNA Script plans to accelerate the design-print test cycle for assay optimization by enabling rapid on-site synthesis of DNA oligos for use in genomics workflows, including endpoint PCR, qPCR, amplicon sequencing and mutagenesis, is made possible. With full control of oligo synthesis on the same day, the SYNTAX system enables DNA oligos to be printed on demand at record speed and without the delays or residue that can occur with outsourced phosphoramidite synthesis services. On-site oligosynthesis also gives researchers confidential control over proprietary sequence information.
“The introduction of the SYNTAX system fulfills our promise to develop and commercialize a benchtop instrument that provides unparalleled access to synthetic DNA and gives users unmatched lead time, control and autonomy over their workflow,” said Thomas ybert, CEO and Co-Founder of DNA Script. “In just a few years we have made rapid progress to improve enzymatic synthesis so that it is comparable to, and in some cases better, chemical synthesis, a 40-year-old technology for applications in molecular biology and genomics, which we only see Beginning.”
The SYNTAX system includes a DNA printer for the laboratory bench, reagent and consumable kits as well as management software. With less than 15 minutes of set-up effort, the SYNTAX system synthesizes 20-mers in about 6 hours and delivers results on the same day and up to 60-mers in about 13 hours that can be operated efficiently overnight. After the synthesis is complete, the SYNTAX printer cleans, quantifies and normalizes the oligos for seamless input into the next step of the research workflow. The software suite monitors reagent levels and enables easy re-ordering of the SYNTAX kit, which includes four inks – A, T, G and C – and enables an integrated workflow in which users can manage DNA print runs, reagents and results.
DNA Script’s EDS technology uses proprietary biochemistry, including sophisticated enzymes, to accelerate nucleic acid synthesis and optimize performance. In contrast to phosphoramidite chemistry, EDS is carried out in an aqueous medium outdoors and without aggressive organic solvents. DNA Script’s EDS technology enables the SYNTAX system to print functional oligos, including those that have proven too difficult in the past to be conventionally chemically based.
For more information on purchasing the SYNTAX system, please visit www.dnascript.com or contact the DNA Script customer support team at Script [email protected] to arrange a demo.
Via DNA script
Founded in 2014, DNA Script is a leading DNA synthesis company with a biology engineering vision to accelerate breakthroughs in the life sciences. The company is pioneering an alternative to phosphoramidite DNA synthesis called Enzymatic DNA Synthesis (EDS) and is making it accessible to laboratories with the first benchtop enzymatic synthesizer, the SYNTAX system. By putting DNA synthesis back in the lab, DNA Script aims to transform life science research through innovative technologies that give researchers unprecedented control and autonomy. www.dnascript.com.
SOURCE DNA Script